Ignite Creation Date:
2024-05-06 @ 7:22 AM
Last Modification Date:
2024-10-26 @ 11:47 AM
Study NCT ID:
NCT02521051
Status:
UNKNOWN
Last Update Posted:
2019-11-26
First Post:
2015-07-20
Brief Title:
Phase III Trial of Alectinib and Bevacizumab in Patients With Advanced Anaplastic Lymphoma Kinase ALK-Positive Non-Small Cell Lung Cancer
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Organization Data
Organization:
Massachusetts General Hospital
Class:
OTHER
Study ID:
15-055
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Massachusetts General Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Justin Gainor MD
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Massachusetts General Hospital
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Genentech Inc | INDUSTRY |